Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 27, 2007

View Archived Issues

Transient improvement in rheumatoid arthritis activity seen with CRx-139

Kiadis to provide Rhitol to physicians participating in phase I/II trial closed for enrollment

Artemisinin derivative shows promise in models of autoimmune inflammatory disease

Recent patents disclose new therapeutic options for neuropsychiatric disorders

New therapeutic agents for endocrine disorders disclosed in recent patents

Ardana reports positive preliminary results from phase II study of teverelix LA

Novel agents for allergic and respiratory disorders described in recent Boehringer Ingelheim patent

Preclinical studies of arthritis therapy target TNF-alpha and Bcl-2

Selective and multitargeted B-Raf inhibitors described at Deciphera

Selective LMP7 proteasome inhibitor shows antirheumatic activity in vivo

P2X7 receptor blockade is associated with reduced joint destruction in inflammatory arthritis

Modulation of 5-HT2 signaling shows benefit in models of inflammatory arthritis

European Commission approves Wyeth Pharmaceuticals' Torisel for renal cell carcinoma

MedImmune initiates phase I clinical trial of CAM-3001 for rheumatoid arthritis

Roche and Maxygen terminate development of MAXY-alpha

Merck & Co. files marketing authorization application with EMEA for vorinostat

LEO Pharma launches ATryn for hereditary antithrombin deficiency

FDA removes hold on Targeted Genetics' phase I/II clinical trial of tgAAC-94

Sygnis and Dr. Reddy's enter 10-year supply agreement for AX-200 for stroke

Daval International gets MHRA approval for phase IIb trial of Aimspro for MS

Mercury develops protein-kinase technology for treatment of type 2 diabetes

VioQuest initiates phase IIa study of Lenocta for the treatment of solid tumors

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 5, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Study identifies CAND1 as therapeutic target in hepatoblastoma
BioWorld Science
Hepatoblastoma is the most common liver cancer during childhood, with limited therapeutic options in aggressive or relapsed cases. NEDDylation is a...
Serotonin receptor modulators for the treatment of OUD
BioWorld Science
Opioid use disorder (OUD) causes high morbidity and mortality rates, with fentanyl driving unprecedented overdose rates. Researchers from the University of...